22 May 2013
Keywords: genta, starts, phi/iia, g3139, study, inc, start
Article | 25 June 1998
Genta Inc is to start a Phase I/IIa study of its bcl-2 antisensedrug, code-named G3139, in combination with dacarbazine ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
21 May 2013
© 2013 thepharmaletter.com